SCHEMBL4021282

SCHEMBL4021282

Cc1ccc(N)cc1-n1cc(-c2cnn(-c3ccccc3)c2C)nn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39
KMT2A Q03164 2/20 0.39
FLT3 P36888 1/20 0.38
GSK3B P49841 1/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRM2 Q14416 1/20 0.38
GRM4 Q14833 1/20 0.38
PTGS2 P35354 5/20 0.38
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021274 0.84 GRM2 (0.46) NPC1RAB9AGRM2PTGS2ALDH1A1
SCHEMBL12398710 0.82 FLT3 (0.39) FLT3GSK3BKDM4ESMN1; SMN2ABL1
SCHEMBL13843757 0.74 PTGDR2 (0.46) NPC1RAB9ASMN1; SMN2ABL1ALDH1A1
SCHEMBL4013457 0.73 TEK (0.52) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL4022855 0.72 NPC1 (0.48) NPC1RAB9A
SCHEMBL2086210 0.72 BRAF (0.51) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL4017535 0.71 MIF (0.51) FLT3GSK3BKDM4EMEN1ABL1
SCHEMBL4017103 0.70 MAPK14 (0.45) NPC1RAB9AABL1BCR
SCHEMBL4018468 0.69 NR4A3 (0.39) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL9906354 0.67 ALDH1A1 (0.43) KDM4EABL1BCRL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531560-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-05-12 US disclosed
US-20060100204-A1 Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100204-A1 Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. NFKBIA, CHUK, IL1B NPC1 1938/4885RAB9A 1991/4885KMT2A 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.